Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 19/20 | 0.78 |
| ▸ | TP53 | P04637 | 12/20 | 0.78 |
| ▸ | THRB | P10828 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329003 | 0.96 | MAPT (0.78) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL3324735 | 0.91 | MAPT (0.78) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL13980951 | 0.90 | MAPT (0.82) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL3320239 | 0.89 | MAPT (0.88) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL3326670 | 0.88 | MAPT (1.00) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL8131762 | 0.87 | MAPT (0.80) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL3323790 | 0.85 | MAPT (0.76) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL3328097 | 0.84 | MAPT (0.75) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL3322843 | 0.83 | MAPT (0.76) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL3323177 | 0.83 | MAPT (0.73) | MAPTTP53THRBPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | claimed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | claimed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | claimed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | claimed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | disclosed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2008116926-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CYBB, NQO1, NOX4 | MAPT 1042/4885TP53 4124/4885THRB 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.